ArticleOncology letters2025
Efficacy and safety of the immune checkpoint inhibitor-radiotherapy combination in advanced/unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Magnetic Resonance-Guided Radiotherapy for Unresectable Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Series and Review of Treatment Options.Current oncology (Toronto, Ont.) · 2026Review
- Immunotherapy in hepatocellular carcinoma: translating mechanistic insights into clinical advances.Clinical and experimental medicine · 2026Review
- Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study.Oncology research · 2026Observational
- Multimodal Conversion Therapy Enabling Curative Resection in Giant Hepatocellular Carcinoma with Arteriovenous Fistula: A Case Report.Journal of hepatocellular carcinoma · 2026Article
- Performance of AI-based machine learning models for overall survival prediction in advanced hepatocellular carcinoma patients receiving immunoradiotherapy.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited treatment options are available for patients with advanced stages of hepatocellular carcinoma (HCC), which is a major global health challenge. The present systematic review and meta-analysis examined the therapeutic potential of the combination of immune checkpoint inhibitors (ICIs) and radiotherapy (RT) for advanced (a)HCC or unresectable HCC. The PubMed, Embase, Cochrane Library and Web of Science databases were searched to identify studies examining the therapeutic efficacy of the ICI-RT combination for aHCC published until August 31, 2024. The following clinical outcomes were analyzed: Objective response rate (ORR), median progression-free survival (mPFS) and median overall survival (mOS). Additionally, targeted subgroup analyses were performed based on tumor thrombus presence and the use of transarterial chemoembolization (TACE) and stereotactic body RT. The present single-arm meta-analysis, encompassing 16 studies involving 633 patients with aHCC or unresectable HCC, revealed that the ICI-RT combination exhibits potent therapeutic efficacy. The pooled ORR of patients in the ICI-RT combination group was 54.4% [95% confidence interval (CI), 46.8-62.0%]. The mPFS and mOS of patients treated with the ICI-RT combination were 10.1 (95% CI, 7.2-12.9) and 18.3 months (95% CI, 14.6-21.9), respectively. The ORR of patients in the TACE combination subgroup was 53.8% (95% CI, 44.6-62.9%). Meanwhile, the ORR and mOS of patients with Barcelona Clinic Liver Cancer stage C tumors were 55.6% (95% CI, 44.3-66.9%) and 21.2 months (95% CI, 13.5-29.0), respectively. These findings suggest that ICI and RT exert synergistic effects. The ICI-RT combination, a promising therapeutic regime for aHCC, is associated with potent efficacy and favorable ORR and survival outcomes. Further studies are needed to optimize treatment strategies and identify patient subgroups who can benefit from this approach. The findings of the present study contribute to advances in aHCC treatment. The protocol for the present systematic review was registered at PROSPERO (registration no. CRD42024583148) and is available in full on the Health Technology Assessment website of the National Institutes of Health (http://www.hta.ac.uk/2283).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.